Related Experiment Videos
Dianhydrogalactitol and neural tumors: an in vitro, in vivo preclinical evaluation
Abstract:
The effects of dianhydrogalactitol on human neuroblastomas in vitro and in vivo as heterotransplants in nude mice were determined. Four neuroblastoma lines and three primitive neuroectodermal tumor lines were found, in vitro, to have different sensitivities to the drug. The most sensitive in in vitro assays was the neuroblastoma line SK-N-Mc. Tumors from patients resistant to cyclophosphamide were sensitive to dianhydrogalactitol in vitro and in nude mice. The lack of increased cytotoxicity in vitro with concentrations greater than 12 micrograms/ml and the lowered degree of weight loss in mice treated with 6 mg/kg/day x 5 consecutive days compared to 15 mg/kg/day x 2 days (either in sequence or with a 3-day interval) suggest that clinical trials with 5-day courses or constant infusions may be more effective than intermittent pulsed doses.
Insights
Dianhydrogalactitol shows promise against neuroblastomas, particularly those resistant to cyclophosphamide. Optimal dosing strategies may involve 5-day courses or continuous infusions for better efficacy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Neuroblastoma is a pediatric cancer with varying treatment responses.
- Cyclophosphamide is a common chemotherapy agent, but resistance can develop.
- Dianhydrogalactitol is an investigational agent with potential anti-cancer activity.
Purpose of the Study:
- To evaluate the efficacy of dianhydrogalactitol against human neuroblastoma cell lines and in vivo models.
- To determine the sensitivity of different neuroblastoma and primitive neuroectodermal tumor lines to dianhydrogalactitol.
- To compare the effectiveness of different dianhydrogalactitol dosing regimens.
Main Methods:
- In vitro drug sensitivity assays were performed on four neuroblastoma and three primitive neuroectodermal tumor lines.
- In vivo efficacy was assessed using heterotransplanted human neuroblastoma tumors in nude mice.
- Different dosing schedules (pulsed vs. continuous) and doses of dianhydrogalactitol were tested.
Main Results:
- Neuroblastoma and primitive neuroectodermal tumor lines exhibited differential sensitivity to dianhydrogalactitol in vitro.
- The SK-N-Mc neuroblastoma line was most sensitive in vitro.
- Tumors resistant to cyclophosphamide showed sensitivity to dianhydrogalactitol both in vitro and in vivo.
- Higher drug concentrations (>12 µg/ml) did not increase in vitro cytotoxicity.
- Reduced weight loss in mice suggested better tolerability with a 5-day course compared to pulsed doses.
Conclusions:
- Dianhydrogalactitol demonstrates activity against human neuroblastomas, including cyclophosphamide-resistant types.
- Optimal clinical dosing may favor 5-day courses or constant infusions over intermittent pulsed schedules.
- Further investigation into dianhydrogalactitol's therapeutic potential and dosing optimization is warranted.